Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 3/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2160851 | 0.94 | CYP4A11 (0.48) | PTPRBCYP4A11CYP4F2LOXL2ALDH1A1 | |
| SCHEMBL8245053 | 0.93 | PTPRB (0.41) | PTPRBCYP4A11CYP4F2LOXL2ALDH1A1 | |
| SCHEMBL2294364 | 0.92 | PTPRB (0.40) | PTPRBCYP4A11CYP4F2LOXL2HPGD | |
| SCHEMBL2289320 | 0.92 | PTPRB (0.40) | PTPRBCYP4A11CYP4F2LOXL2HPGD | |
| SCHEMBL8158261 | 0.86 | CYP4F2 (0.48) | PTPRBCYP4A11CYP4F2ALDH1A1TP53 | |
| SCHEMBL8240083 | 0.86 | PTPRB (0.37) | PTPRBCYP4A11CYP4F2LOXL2HPGD | |
| SCHEMBL2294402 | 0.83 | PTPRB (0.40) | PTPRBCYP4A11CYP4F2LOXL2ALDH1A1 | |
| SCHEMBL2294163 | 0.82 | CYP4A11 (0.41) | PTPRBCYP4A11CYP4F2LOXL2ALDH1A1 | |
| SCHEMBL2674860 | 0.82 | PTPRB (0.33) | PTPRBCYP4A11CYP4F2LOXL2ALDH1A1 | |
| SCHEMBL21570565 | 0.80 | PTPRB (0.55) | PTPRBCYP4A11CYP4F2LOXL2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940769-B1 | DICARBOXYLIC ACID DERIVATIVES AND THEIR USE | BAYER IP GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-1940769-B1 | DICARBOXYLIC ACID DERIVATIVES AND THEIR USE | BAYER IP GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| US-8609727-B2 | Dicarboxylic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| US-8217063-B2 | Lactam-substituted dicarboxylic acids and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-07-10 | — | — | US | disclosed |
| US-8217063-B2 | Lactam-substituted dicarboxylic acids and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-07-10 | — | — | US | disclosed |
| US-8217063-B2 | Lactam-substituted dicarboxylic acids and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-07-10 | — | — | US | disclosed |
| EP-2142504-B1 | LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF | Bayer Pharma AG (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-20100197680-A1 | LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197680-A1 | LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197680-A1 | LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100029772-A1 | Dicarboxylic Acid Derivatives and their Use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029772-A1 | Dicarboxylic Acid Derivatives and their Use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029772-A1 | Dicarboxylic Acid Derivatives and their Use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | US | disclosed |
| EP-2142504-A2 | LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF | Bayer Schering Pharma AG (DE) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119457-A2 | LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119457-A2 | LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-09 | — | — | WO | disclosed |
| EP-1940769-A1 | DICARBOXYLIC ACID DERIVATIVES AND THEIR USE | Bayer HealthCare AG (DE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045433-A1 | DICARBOXYLIC ACID DERIVATIVES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045433-A1 | DICARBOXYLIC ACID DERIVATIVES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197680-A1 | LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF | DDO, DDC, BCAT2 | PTPRB 3780/4885CYP4A11 2160/4885CYP4F2 672/4885 |
| US-20100029772-A1 | Dicarboxylic Acid Derivatives and their Use | PC, SLC25A1, GOT2 | PTPRB 3855/4885CYP4A11 1566/4885CYP4F2 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.